The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy?
 
Evan Rosenbaum
Stock and Other Ownership Interests - Iovance Biotherapeutics; PMV Pharma
Research Funding - Arcus Biosciences; GlaxoSmithKline; Incyte
 
Kenneth Seier
No Relationships to Disclose
 
Martina Bradic
No Relationships to Disclose
 
Rhoena Desir
Employment - Memorial Sloan-Kettering Cancer Center (I)
 
Ciara Marie Kelly
Employment - Daichii Sankyo (I)
Stock and Other Ownership Interests - daichii sankyo (I)
Consulting or Advisory Role - ChemoCentryx; Deciphera; Exicure; Immunicum; Kartos Therapeutics; SERVIER
Research Funding - AGIOS (Inst); Amgen (Inst); Curadev (Inst); Exicure (Inst); IDRx (Inst); Kartos Therapeutics (Inst); Merck (Inst); Regeneron (Inst); Servier (Inst); xencor (Inst)
 
Sujana Movva
Consulting or Advisory Role - Genmab
Research Funding - Ascentage Pharma Group (Inst); Hutchison MediPharma (Inst); Jaz (Inst); Pfizer (Inst); Pfizer (Inst); PTC (Inst); Trillium Therapeutics (Inst)
 
Viswatej Avutu
No Relationships to Disclose
 
Lauren Baker Banks
No Relationships to Disclose
 
Jason Earl Chan
Research Funding - Cytek Biosciences (Inst); Ono Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for methods to identify and treat high-plasticity cell state driving tumor progression in lung cancer
 
Ping Chi
Stock and Other Ownership Interests - ORIC Pharmaceuticals (I)
Consulting or Advisory Role - Deciphera; NewBay Pharma
Research Funding - Deciphera (Inst); NewBay Pharma (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from ORIC (I)
Travel, Accommodations, Expenses - NewBay Pharma
 
Mark Andrew Dickson
Research Funding - AADi (Inst); Lilly (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Mary Louise Keohan
No Relationships to Disclose
 
Mrinal M. Gounder
Honoraria - Gerson Lehrman Group; Great Debates and Updates; Guidepoint Global; Med Learning Group; Medscape; MJH/PER; OncLive/MJH Life Sciences; Research to Practice; touchIME
Consulting or Advisory Role - AADi; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Ikena Oncology; Karyopharm Therapeutics; Rain Therapeutics; Regeneron; Springworks Therapeutics; TYME
Research Funding - AADi (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Erasca, Inc (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Ikena Oncology (Inst); Kymera (Inst); Rain Oncology (Inst); Regeneron (Inst); SERVIER (Inst); SpringWorks Therapeutics (Inst); Tango Therapeutics (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Foundation Medicine
 
Robert G. Maki
Consulting or Advisory Role - Boehringer Ingelheim; Deciphera; Eisai; GlaxoSmithKline; Medtronic; PEEL Therapeutics
Speakers' Bureau - MJH Life Sciences
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); InhibRx (Inst); Regeneron (Inst); SARC: Sarcoma Alliance for Research though Collaboration (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - Stand up to Cancer
(OPTIONAL) Uncompensated Relationships - Fondazione Enrico Pallazzo
 
Samuel Singer
No Relationships to Disclose
 
Li-Xuan Qin
Employment - Sironax (I)
Leadership - Sironax (I)
Stock and Other Ownership Interests - Sironax (I)
 
Cristina R. Antonescu
No Relationships to Disclose
 
William D. Tap
Leadership - AstraZeneca; Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; AmMax Bio; Ayala Pharmaceuticals; Bayer; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; inhibrx; Kowa Pharmaceutical; Lilly; Medpacto; PharmaEssential; Servier
Research Funding - Avacta Life Sciences (Inst); BioAtla (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Theseus Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Sandra P. D'Angelo
Honoraria - AADi; Adaptimmune; GI Innovation; GlaxoSmithKline; Incyte; Nektar; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - AADi; Adaptimmune; GI Innovation; GlaxoSmithKline; Incyte; Nektar; Pfizer; Rain Therapeutics; Servier
Research Funding - Amgen; Bristol-Myers Squibb.; Deciphera; EMD Serono; Incyte; Merck; Nektar
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar
Other Relationship - Adaptimmune; GlaxoSmithKline; Merck; Nektar